Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide.
$287.47-0.35%
报价 2026-11-17
市值
$41.68B
EV
$40.97B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -34.1%
$182.65$436.00
筛选结果
pipeline · 2026-11-17Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-17未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 1.3x | -1.10 → -0.54 | — |
| FY+32028-12 | 1.5x | -1.10 → 1.06(扭亏) | 272.0 |
毛利率 65% · TTM 收入 $2909M · 基数 EPS -1.10(调整后)
电话会信号
辅助标签Q3 20262026-11-05
扩产需求加速上调指引盈利拐点
指引 上调
信心 5
分析师 4
“We are setting the goal to double revenues in the next 3 years, reaching $6 billion in revenue in 2029.”
原文引用(4)
- 扩产:we have accelerated a lot of investments in our pharma specific offerings, commercial team, and operations that drive both CapEx and operating expenses higher
- 需求加速:Over the last 9 months, we have seen a real surge in biopharma demand for our MRD technology, in clinical trials
- 上调指引:we are raising our full-year 2026 revenue guidance to a range of $3.05 billion to $3.35 billion up from the $2.85 billion to $2.91 billion
- 盈利拐点:it will be possible for us to continue to deliver another quarter of positive free cash flow and improving EBITDA in Q4
蓝色标签在暴涨研究中略有区分度;悬停查看口径。
研究结论
L2 2026-11-12 · L3 2026-11-12全文 ↓Bull
$162.00
-49.35% · PE
Base
$53.50
-83.27% · PE
Bear
$122.57
-61.68% · EV/Sales
Bull
Base
Bear
现价 $287.47
### 5.1 概率加权结果
基本面判断
›最强证据
检测量(尤其肿瘤 MRD +60.9%)与 ASP 双升驱动收入 +34%,亏损连续收窄,指引连续大幅上修,方向性基本面向上 (Q3 2026 call; 8-K 2026-11-05)。
›最大反证/不确定性
利润改善靠收入摊薄而非费用节制,CFO 依赖 SBC 与应收变动,FCF 被 capex 吞噬;true-up 与 ASP 路径的可持续性缺少跨期硬证据;诉讼结果未定。
›研究置信度
中等偏低——收入增长证据较扎实,但盈利质量、现金转化与 ASP 长期路径的关键输入不足,部分项目"无法检验"。
›是否进入 Layer 3 估值?有条件
收入与检测量可建模,ASP 路径与费用纪律有管理层指引可锚定,值得检验"2027 利润率拐点"的预期差;但需先补齐应收账龄、SBC 口径与 consensus EPS 定义,否则利润率与 FCF 模型输入不足。
接下来盯什么(5 项)
- 剔除 true-up 后的季度营收增速与环比检测增量:→ 当前基准:Q3 剔除 true-up 同比 >40%、MRD 环比 +3.3 万例 → 验证条件:下季环比增量是否维持 2.5 万例以上、true-up 占比是否继续下降 → 调整假设 A 与收入路径。
- Signatera ASP 与 MolDX 覆盖进展:→ 当前基准:约 $1.29k,9–10 项提交在途 → 验证条件:未来 12 个月是否有新增适应症覆盖落地、ASP 是否续升 → 调整假设 A。
- 经营费用增速 vs 收入增速:→ 当前基准:Q3 R&D +39.8%、SG&A +8.1% → 验证条件:2027 年 OpEx 是否落在 +10%–12% 区间 → 调整假设 B 与利润率拐点时点。
- 应收账款与经营现金流:→ 当前基准:前九月应收 +$174.8M、FCF $14.7M → 验证条件:应收增速是否低于收入增速、Q4 FCF 是否为正 → 调整假设 C。
- 诉讼与或有对价:→ 当前基准:Guardant/Ravgen 上诉中、或有对价上限 $175M → 验证条件:上诉结果或和解、里程碑触发 → 调整净负债与稀释假设。
历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| NTRANatera, Inc. | $41.68B | -0.4% | – | 64.7% | – | – | 797.3x | |
| TEVATeva Pharmaceutical Industries Limited | $49.73B | +0.1% | -0.6% | 55.5% | 93.0x | 30.3x | 39.5x | |
| WATWaters Corporation | $44.21B | -0.8% | +105.3% | 58.9% | 28.0x | 18.3x | 151.6x | 高增长 |
| IQVIQVIA Holdings Inc. | $42.45B | -2.7% | +8.0% | 32.9% | 33.1x | 16.6x | 16.9x | |
| MTDMettler-Toledo International Inc. | $34.07B | -0.8% | +6.7% | 57.5% | 29.1x | 22.2x | 39.1x | |
| ILMNIllumina, Inc. | $30.63B | +2.3% | +7.6% | 66.4% | 49.5x | 30.8x | 43.1x | |
| DXCMDexCom, Inc. | $30.6B | +0.5% | +12.4% | 63.4% | 34.4x | 21.8x | 23.9x | GARP |
| PHGKoninklijke Philips N.V. | $28.95B | -0.8% | – | 45.2% | 24.5x | 10.1x | – | |
| DGXQuest Diagnostics Incorporated | $28.2B | -2.2% | +10.0% | 33.7% | 24.3x | 15.6x | 21.0x | GARP |
| 同行中位数 | – | – | +8.0% | 56.5% | 31.1x | 20.0x | 39.1x |
研究全文
财务报表
| Metric | 2026-09-30 Q3 2026 | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 | 2025-03-31 Q1 2025 | 2024-12-31 Q4 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $794M | $752.8M | $696.6M | $665.5M | $592.2M | $546.6M | $501.8M | $476.1M |
| Gross Margin | 64.7% | 64.5% | 64.8% | 67.1% | 64.9% | 63.5% | 63.2% | 62.9% |
| Operating Margin | -8.6% | -10.1% | -13.4% | -3.4% | -16.5% | -20.2% | -15.8% | -13.6% |
| Net Income | $-59.9M | $-67M | $-85.1M | $47.3M | $-87.5M | $-100.9M | $-66.9M | $-53.8M |
| Diluted EPS | -0.42 | -0.47 | -0.6 | 0.35 | -0.64 | -0.74 | -0.5 | -0.41 |
| Operating Cash Flow | $43.9M | $54.8M | $40.2M | $73.9M | $59.4M | $37.6M | $44.5M | $52.9M |
研究材料
Filing 摘要